Abstract
Streptozotocin (STZ), derived from Streptomyces achromogenes, is a glucosamine-nitrosourea compound widely recognized for its ability to induce diabetes in rodent models. This review article delves into the pharmacological actions of STZ, examining its mechanisms of action, toxic effects, and its utility in inducing diabetic animal models. By understanding STZ's intricate pharmacological profile, researchers can better harness its potential in studying diabetes and its complications.
We provide Streptozotocin Stz CAS 18883-66-4, please refer to the following website for detailed specifications and product information.
Keywords: Streptozotocin, diabetes, pharmacological actions, animal models, β-cell toxicity
|
|
|
Introduction
Diabetes mellitus, characterized by hyperglycemia resulting from defects in insulin secretion or action, poses a significant global health burden. Streptozotocin (STZ), a chemical compound isolated from Streptomyces achromogenes, has emerged as a pivotal tool in diabetes research due to its ability to selectively destroy pancreatic β-cells, leading to insulin deficiency and subsequently diabetes. This review aims to provide a comprehensive understanding of STZ's pharmacological actions, its mechanisms of β-cell toxicity, and its applications in inducing diabetic animal models.
Chemical Structure and Properties
STZ belongs to the class of amino glucose-nitrosoureas. Chemically, it consists of a glucosamine moiety linked to a nitrosourea group. This unique structure allows STZ to enter β-cells via the GLUT2 glucose transporter, a low-affinity transporter predominantly expressed in β-cells. Once inside the cell, STZ undergoes metabolic activation, leading to its pharmacological effects.
Mechanisms of β-Cell Toxicity
The β-cell toxicity of STZ is multifaceted, involving several mechanisms:
DNA Alkylation and Damage
STZ directly alkylates DNA, causing strand breaks, base modifications, and the formation of DNA adducts. This DNA damage triggers the activation of poly(ADP-ribose) polymerase (PARP), leading to the consumption of cellular ATP and NAD+, ultimately resulting in β-cell death.
01
Induction of Oxidative Stress
The metabolism of STZ generates reactive oxygen species (ROS), such as superoxide radicals, which contribute to oxidative stress within β-cells. Oxidative stress disrupts mitochondrial function, promotes lipid peroxidation, and enhances DNA damage, further exacerbating β-cell toxicity.
02
Activation of Apoptotic Pathways
STZ-induced DNA damage and oxidative stress activate intrinsic and extrinsic apoptotic pathways. This leads to the cleavage of caspase enzymes, membrane phospholipid flip-flop, and eventually, β-cell apoptosis.
03
Impairment of Insulin Secretion and Synthesis
STZ disrupts insulin secretion by impairing glucose-stimulated insulin release and reducing insulin gene expression. Additionally, it inhibits the synthesis of insulin biosynthetic enzymes, further compromising insulin production.
04
Inflammatory Responses
STZ-induced β-cell damage triggers an inflammatory response, characterized by the infiltration of immune cells into the islets of Langerhans. This inflammatory milieu exacerbates β-cell death and impairs islet function.
05
Pharmacological Actions
Given its β-cell toxicity, STZ has found widespread application in inducing diabetic animal models, primarily in rodents. These models are crucial for studying the pathogenesis of diabetes, evaluating therapeutic interventions, and understanding the complications associated with the disease.
Firstly
Streptozotocin specifically targets and damages the beta cells within the islets of Langerhans in the pancreas. Beta cells are responsible for the production and secretion of insulin, a hormone crucial for regulating blood glucose levels. By destroying these cells, Streptozotocin disrupts the normal production of insulin, leading to hyperglycemia (elevated blood glucose levels), which mimics the condition of diabetes mellitus in humans.
Secondly
The damage caused by Streptozotocin to beta cells is irreversible. Once the cells are destroyed, they cannot be regenerated, resulting in a persistent state of insulin deficiency. This makes Streptozotocin an effective tool for creating a stable diabetic animal model for long-term studies.
Moreover
Streptozotocin-induced diabetes in animals shares many similarities with type 1 diabetes in humans, including the development of insulin deficiency, hyperglycemia, and associated complications such as retinopathy, neuropathy, and nephropathy. Therefore, this model is widely used in research to investigate the pathogenesis, prevention, and treatment of diabetes and its complications.
|
|
|
Applications
Induction of Diabetic Animal Models
STZ-induced diabetic models mimic Type 1 diabetes, characterized by insulin deficiency due to β-cell destruction. By administering STZ to rodents, researchers can reliably induce hyperglycemia, glucose intolerance, and insulin deficiency, mimicking the human disease state.
01
Study of Diabetic Complications
Diabetic animal models induced by STZ are invaluable for studying the various complications associated with diabetes, including neuropathy, nephropathy, retinopathy, and cardiovascular disease. These models allow for the investigation of the underlying mechanisms, the identification of biomarkers, and the testing of potential therapeutic strategies.
02
Evaluation of Therapeutics
STZ-induced diabetic models serve as a platform for evaluating novel therapeutic agents targeting diabetes and its complications. By assessing the efficacy and safety of these agents in diabetic animals, researchers can prioritize candidates for further clinical development.
03
Insight into β-Cell Regeneration
STZ-induced diabetes models also provide insights into β-cell regeneration and islet neogenesis. By studying the mechanisms underlying β-cell recovery and islet restoration in these models, researchers can identify potential therapeutic strategies for β-cell replacement in diabetes.
04
Adverse Effects
STZ is known for its toxicity, which necessitates strict control over dosage and administration methods to prevent unnecessary harm to experimental animals. Some of the adverse reactions observed in animals include nausea, vomiting, and diarrhea. Although these reactions are mostly mild and reversible, they still require attention from researchers. Additionally, long-term use of STZ may impact liver and kidney functions, necessitating close monitoring of relevant indicators during its application.
Usage Precautions
Dosage Control
The dosage of STZ should be carefully determined based on pre-experimental results rather than blindly following literature or others' dosages. Factors such as average animal weight, fasting resistance, fasting duration, injection timing, and previous feeding conditions can all affect the appropriate dosage.
01
Administration Method
STZ is unstable and prone to inactivation. Therefore, it should be quickly weighed and the remaining reagent stored in a dry and light-protected environment, preferably wrapped in dry aluminum foil. When injecting, it is advisable to dissolve STZ in batches according to one's level of proficiency to avoid wasting the drug.
02
Animal Preparation
Animals should be fasted for at least 12 hours before STZ administration to enhance the drug's efficacy on pancreatic beta cells. The longer the fasting period, the more pronounced the drug's effect, allowing for a reduction in STZ dosage.
03
Monitoring and Follow-up
Close monitoring of animals' health status and physiological indicators is essential after STZ administration. In cases where the desired model is not achieved, supplementary injections may be considered, but this should be guided by specific experimental protocols.
04
Conclusion
Streptozotocin, with its unique ability to selectively destroy β-cells, has revolutionized diabetes research. By understanding its pharmacological actions, mechanisms of β-cell toxicity, and applications in inducing diabetic animal models, researchers can harness its potential to study diabetes and its complications more effectively. However, it is imperative to balance the benefits of STZ with its toxic effects, ensuring ethical and safe conduct in animal studies. Future research should focus on refining STZ-induced diabetic models, exploring alternative inducers, and developing novel therapeutic strategies to combat diabetes.
In conclusion, Streptozotocin remains a cornerstone in diabetes research, offering insights into the pathogenesis of the disease and facilitating the development of novel therapeutic interventions. By continuing to explore its pharmacological actions and refining its applications, the scientific community can further advance our understanding and treatment of diabetes.